Compare OPAD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | TVRD |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 36.8M |
| IPO Year | N/A | N/A |
| Metric | OPAD | TVRD |
|---|---|---|
| Price | $0.73 | $2.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $1.83 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 688.4K | 37.6K |
| Earning Date | 05-04-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $3.05 |
| 52 Week High | $6.35 | $43.65 |
| Indicator | OPAD | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 28.56 |
| Support Level | $0.71 | N/A |
| Resistance Level | $0.82 | $4.52 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 69.22 | 6.50 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.